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Renal cell carcinomaAbstract Objective: This study aimed to assess prognosis of isolated local recurrence (ILR) of
renal cell carcinoma (RCC) after radical nephrectomy (RN).
Patients and Methods: This retrospective study involved 22 cases (16 men and 6 women) of ILR
from two centers with a mean age of 60.1 ± 8.5 years. All cases were managed surgically.
Results: Primary tumors were mainly clear cell carcinoma (n= 17). Nine patients had T3 and T4
tumors. Local recurrence involved mainly the operative bed (n= 17); 4 among them had nodal
recurrence as well. The median interval to local recurrence was 13.5 months (7–25 months). Stages
T3 and T4 were signiﬁcantly associated with shorter interval. Complete excision was possible in
9 patients (41%); 8 tumors were irresectable. It was associated with signiﬁcantly higher overall
and median disease-free survival (DFS). Advanced disease stage (p= 0.002) and shorter interval
to recurrence (p< 0.001) were associated with higher proportion of incomplete excision. The
median overall survival and DFS were 15 months (95% CI: 4.4–25.6) and 10 months (95% CI:
4.5–15.5), respectively. Overall and DF survival were signiﬁcantly better in patients with nodal
recurrence only, complete excision of the recurrence and interval from nephrectomy to recurrence
>15 months.
Conclusion: ILR after radical nephrectomy for RCC is more common with more advanced stages,
where interval to recurrence tends to be shorter. The management should be surgical, which was
possible in nearly 60% of cases. Complete excision was associated with better overall and disease
free survival.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.
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Renal tumors account for nearly 2% of new cancer cases and
are the 7th leading cause of death due to cancer [1]. More than
80% of kidney cancers are renal cell carcinoma (RCC) [2].
RCC is the most common malignancy arising in the renal
parenchyma [3]. Incidence of RCC is higher in Europe and
North America compared to Asia and Africa. In men, the inci-
dence in developing countries was nearly half of that in devel-
oped countries. Jemal et al. reported the cumulative risk of
RCC in developing countries of 0.03% compared to 1.4% in
developed countries [4].
Approximately 30% of patients with RCC present with
locally advanced or metastatic disease [5]. Lymph node
involvement is associated with a 5-year survival rate of
5–30% [6]. Patients with lymphadenopathy are 3–4 times more
likely to have distant metastasis [7]. About 13% of patients
present with metastatic disease at the time of diagnosis [8].
Surgical treatment remains the only effective therapy for
localized renal cell carcinoma [9]. Systemic medical methods
of treating metastatic renal cell carcinoma have limited efﬁcacy
and are under evaluation. However, the past 10 years have
shown a dramatic increase in the development of new agents
for the treatment of advanced RCC. New agents have been
approved for this disease [10].
Modern imaging techniques and strict follow-up protocols
have shown that loco-regional recurrence will occur in about
2% of patients after radical nephrectomy for localized RCC
[9,11]. Recurrent lesions may affect the ipsilateral adrenal
gland, inadequately excised regional lymph nodes or the renal
bed. Unintended perioperative implantation of tumor may
cause local relapse [12].
The isolated local recurrence of RCC after radical nephrec-
tomy creates a difﬁcult therapeutic decision because these
patients are at high risk of distant metastatic disease [13]. Sur-
gical treatment of local recurrences often conveys signiﬁcant
perioperative morbidity [14,15]. Surgical removal of local
recurrence in the absence of metastatic disease appears to be
the only theoretically curative treatment option [9].
However, there is no standard treatment for this rare con-
dition. Relatively few series of treatment for local recurrence
of kidney cancer have been published. Thus, we designed this
study to assess the prognosis of isolated loco-regional recur-
rences after radical nephrectomy for RCC.
Patients and methods
This retrospective study reviewed databases of surgical
departments at the National Cancer Institute (NCI), Cairo
University and in Fayoum Teaching Hospital, Fayoum
University between March 2004 and January 2012. The study
identiﬁed 22 cases (16 men and 6 women) of isolated loco-
regional recurrences after radical nephrectomy for unilateral
localized RCC. Patients with distant metastases were excluded
by a work-up of bone scan, CT of the chest, abdomen and pel-
vis and PET CT in some cases. The total number of radical
nephrectomies were 626 including cases operated in the NCI
and Fayoum Teaching Hospital in addition to cases referred
to the NCI with recurrence.
Data retrieved included initial pathological type, disease
stage, histological grade, location of recurrence and excisionof recurrence. Overall and disease free survival after excision
of recurrence were calculated. Overall survival (OS) was calcu-
lated from the date of diagnosis of local recurrence to the date
of death or last follow up visit. Disease-free survival (DFS)
was calculated from the date of curative surgical excision to
the date of local or distant recurrence or death.
Statistical methods
Data were analyzed using IBM SPSS Advanced Statistics
version 20.0 (SPSS Inc., Chicago, IL). Chi-square test (Fisher’s
exact test) was used to examine the relation between qualita-
tive variables. For quantitative data, comparison between
two groups was done using Mann–Whitney test. Survival
analysis was done using the Kaplan–Meier method and
comparison between two survival curves was done using
log-rank test. A p-value < 0.05 was considered signiﬁcant.Results
The mean age at the time of local recurrence was
60.1 ± 8.5 years. The median interval between nephrectomy
and recurrence was 13.5 months (7–25 months). The median
follow up time was 7.5 months (2–22 months).
Table 1 shows the clinical characteristics of the primary
tumors in the studied group of 22 patients. The main type of
tumors was clear cell carcinoma (n= 17). Tumors were mainly
on the left side. Nine patients had T3 and T4 tumors and 5 had
nodal metastases. Local recurrence involved mainly the opera-
tive bed (n= 17); 4 of these patients had nodal recurrence as
well. Eight tumors were irresectable (Table 2).
Advanced stage (III or IV), T3 or T4 tumors and tumors
10 cm or larger in largest diameter were signiﬁcantly associ-
ated with shorter interval between nephrectomy and occur-
rence of recurrence (Table 3). Table 4 shows the relation
between interval to recurrence and clinical characteristics of
1ry tumor and statistical analysis categorized two groups of
patients 615 months and >15 months. Stage T3 or T4 carries
about 3 times the risk of interval to recurrence 615 months
(OR: 3.3, 95% CI: 1.4–7.3). Interval to recurrence was signif-
icantly longer in patients in whom complete excision of the
local recurrence was possible (18.9 ± 4.4 months) compared
to cases with residual mass (13.2 ± 1.5 months, p= 0.023)
and irresectable tumors (11.1 ± 2.7 months, p= 0.001)
(Table 4).
The surgical excision was divided to complete (n= 9) and
not complete (n= 13) including cases with residual tumor
and irresectable masses. Advanced disease stage and shorter
interval to recurrence were associated with higher proportion
of patients in whom complete excision was not possible
(p 0.002, and <0.001, respectively) (Table 4).
The median OS of the 22 patients was 15 months (95% CI:
4.4–25.6). The cumulative OS proportion at 1 year was 53.8%.
The median DFS survival of the 22 patients was 10 months
(95% CI: 4.5–15.5). The cumulative DFS proportion at 1 year
was 37.7%. Overall survival was signiﬁcantly better in patients
with nodal recurrence only (p< 0.001), complete excision of
the recurrence (p< 0.001) and interval from nephrectomy to
recurrence >15 months (p= 0.016) (Fig. 1). Similarly, DFS
was signiﬁcantly better in these conditions (Table 5).
Table 3 Relation between interval from nephrectomy to
occurrence of recurrence and clinical characteristics of the
primary tumor.
Description p Value
T-stage
T1 & T2 (n= 13) 18 (9–25) 0.007
T3 & T4 (n= 9) 11 (7–15)
Surgical stage
Stage I & II (n= 12) 18 (9–25) 0.021
Stage III & IV (n= 10) 12 (7–18)
Pathological type
Clear cell carcinoma (n= 17) 15 (9–25)
Papillary carcinoma (n= 4) 11 (10–18)
Spindle cell carcinoma (n= 1) 7.0 *
Nuclear grade
1 & 2 (n= 15) 15 (9–25)
3 & 4 (n= 7) 13 (7–19) 0.185
Tumor size
Largest diameter < 10 cm (n= 13) 18 (7–25)
Largest diameterP 10 cm (n= 9) 12 (9–14) 0.017
N-stage
N0 (n= 17) 14 (9–25)
N1 (n= 5) 13 (7–18) 0.319
* No statistical analysis due to small number of cases in subgroups.
Table 1 Clinical characteristics of the studied group (n= 22).
Number Percentage
Pathological type
Clear cell carcinoma 17 77.3
Papillary carcinoma 4 18.2
Spindle cell carcinoma 1 4.5
Laterality
Right 8 36.4
Left 14 63.6
T stage
T1b 8 36.4
T2a 2 9.1
T2b 3 13.6
T3 7 31.8
T4 2 9.1
N stage
N0 17 77.3
N1 5 22.7
Surgical stage
I 7 31.8
II 5 22.7
III 8 36.4
IV 2 9.1
Nuclear grade
1 2 9.1
2 13 59.1
3 5 22.7
4 2 9.1
Largest diameter of the tumor 8.0 (4.0–13.0)
Table 2 Characteristics of isolated local recurrence in the
studied group (n= 22).
Number Percentage
Location of recurrence
Operative bed 13 59.1
Nodal 5 22.7
Both 4 18.2
Excision of recurrence
Complete 9 40.9
Residual 5 22.7
Irresectable 8 36.4
Interval to recurrence, median (Range) 13.5 (7.0–25.0)
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In the current series of 22 patients with isolated local recur-
rence following radical nephrectomy for RCC, tumor recur-
rence was mainly in the operative bed (n= 17). Advanced
stage (T3 or T4) carries 3.3 times the risk of shorter interval
from nephrectomy to recurrence (OR: 3.3, 95% CI: 1.4–7.3).
Surgical excision was complete in 9 patients, incomplete in 5
and impossible in 8 patients. Advanced disease stage and
shorter interval to recurrence were associated with higher pro-
portion of patients in whom complete excision was not possi-
ble (p 0.002, and <0.001, respectively). The median OS of the22 patients was 15 months (95% CI: 4.4–25.6) and the median
DFS survival was 10 months (95% CI: 4.5–15.5). Overall and
DF survival were signiﬁcantly better in patients with nodal
recurrence only, complete excision of the recurrence and inter-
val from nephrectomy to recurrence >15 months.
The study identiﬁed 22 cases among 626 cases (3.5%). This
ﬁgure was relatively high compared to the most modern series
where it was about 2% [16]. In fact, the actual proportion is
less than this because some of the referred cases were operated
on by surgeons outside NCI and Fayoum teaching hospital.
This is because NCI is the main and ﬁrst oncology center in
Egypt and still considered the main oncology referral center
for all Egyptian hospitals all over the republic.
The median interval between nephrectomy and recurrence
was 13.5 months (7–25 months). Advanced stage was signiﬁ-
cantly associated with shorter interval. This was comparable
to previous studies [11,16,17]. Itano et al. reported a mean time
to metastasis of 1.6 years in 19 patients [11]. Master et al.
detected isolated renal fossa recurrence after a mean interval
of 17 months [16].
In a multivariable logistic regression analysis, T stage > 1
was the independent factor for early recurrence [18]. After a
median follow up of 42 months of 495 patients who underwent
nephrectomy for RCC, Stephenson et al. found that the rate,
time and site of relapse were associated with pathological stage
[19].
The risk of local recurrence in the current series was higher
in stages T3 and T4. This was conﬁrmed in previous studies
[20,21]. However, in studies of Schro¨dter et al., Itano et al.,
and Gogus et al. there was a considerable number of T1 and
low risk T1 cases with local recurrence [9,11,22]. In the current
series, overall and DFS were better in association with interval
to recurrence >15 months. Schrodter et al. reported similar
Table 4 Relation between mode of surgical excision and clinical characteristics of the primary tumor and location and interval to
recurrence.
Excision of recurrence p Value
Complete Not complete
T-stage
T1 & T2 (n= 13) 9 (69.2%) 4 (30.8%) 0.002
T3 & T4 (n= 9) 0 (0.0%) 9 (100.0%)
Surgical stage
Stage I & II (n= 12) 8 (66.7%) 4 (33.3%) 0.011
Stage III & IV (n= 10) 1 (10.0%) 9 (90.0%)
Pathological type
Clear cell carcinoma (n= 17) 8 (47.1%) 9 (52.9%) *
Papillary carcinoma (n= 4) 1 (25.0%) 3 (75.0%)
Spindle cell carcinoma (n= 1) 0 (0.0%) 1 (100.0%)
Nuclear grade
1 & 2 (n= 15) 7 (46.7%) 8 (53.3%)
3 & 4 (n= 7) 2 (28.6%) 5 (71.4%) 0.648
Location of recurrence
Operative bed 6 (35.3%) 11 (64.7%) 0.609
Nodal only 3 (60.0%) 2 (40.0%)
Interval to recurrence
>15 months 8 (88.9%) 1 (11.1%)
615 months 1 (7.7%) 12 (92.3%) <0.001
* No statistical analysis due to small number of cases in subgroups.
Fig. 1 Overall survival in relation to the interval between
primary surgery and occurrence of recurrence.
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size of recurrence signiﬁcantly smaller in surviving patients [9].
The management strategy in the current series was surgical
excision where complete tumor excision was achieved in 9/
22 patients (41%). Complete surgical excision was possible
with earlier disease stage and longer interval to recurrence.
Complete excision was associated with signiﬁcantly higher
overall and DFS survival. Median overall survival was
15 months in cases of complete excision vs. 6 months in caseswith incomplete excision (p< 0.001). In the past, surgical
treatment of local recurrences was associated with signiﬁcant
morbidity and mortality due to late diagnosis [15,23].
Margulis et al. reported median recurrence-free of
11 months in a group of 54 patients with isolated local recur-
rence after radical nephrectomy. They concluded that aggres-
sive resection of recurrences resulted in long-lasting local
control and higher survival [24]. In 16 patients, Sandhu et al.
found 2 inoperable cases. Complete surgical excision was asso-
ciated with prolonged disease-free survival [12]. Also, complete
surgical resection was associated with improved survival in a
series of 34 patients [25].
Go¨g˘u¨s et al. proved that patients can beneﬁt from aggressive
surgical approach despite signiﬁcant complications in such type
of surgery [22]. The overall survival rate in this series was
53.8%. Esrig et al. reported 55% survival rate at 1 year after
aggressive surgical approach in 11 patients [15]. In 30 patients
with isolated fossa recurrence, Itano et al. reported a 5-year sur-
vival rate of 51% after extensive surgery [11]. Higher median
survival of 23.5 months was reported by Tanguay et al. [26].
In conclusion, isolated local recurrence after primary
radical nephrectomy for RCC is more common with more
advanced stages, where the interval to recurrence tends to be
shorter. The management of these cases should be surgical,
which was possible in nearly 60% of cases. Complete excision
was possible with earlier stages and longer interval to recur-
rence and associated with better overall and disease free
survival.
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Table 5 Factors affecting the overall and disease free survival of the studied groups.
n Cumulative survival
proportion at 1 year
Median survival
(95% CI), months
p Value
Overall survival 22 53.8% 15.0 (4.4–25.6)
Initial pathology
Clear cell carcinoma 17 66.0% 0.082
Papillary carcinoma 5 20.0% 7.0 (0.6–13.4)
T stage
T1 & T2 13 83.3% <0.001
T3 & T4 9 0.0% 5.0 (2.7–7.3)
N stage
N0 17 60.0% 17.0 (3.8–30.2) 0.240
N1 5 30.0% 7.0 (2.3–11.7)
Location of recurrence
Operative bed 13 58.3% 15.0 (0.0–30.6) *
Nodal 5 75.0% *
Both 4 0.0% 15.0 (4.4–25.6)
Excision of recurrence
Complete 9 100.0% 15.0 (4.4–25.6) <0.001
Not complete 13 11.4 6.0 (4.6–7.4)
Interval to recurrence
>15 months 9 88.9% * 0.016
615 months 13 21.8% 7.0 (5.1–8.9)
DFS survival 22 37.7% 10.0 (4.5–15.5)
Initial pathology
Clear cell carcinoma 17 51.3% 15.0 (6.1–23.9) 0.037
Papillary carcinoma 5 0.0% 7.0 (0.6–13.4)
T stage
T1 & T2 13 58.3% 15.0 (7.3–22.7) <0.001
T3 & T4 9 0.0% 5.0 (2.7–7.3)
N stage
N0 17 46.7% 11.0 (2.2–19.8) 0.113
N1 5 0.0% 7.0 (2.3–11.7)
Location of recurrence
Operative bed 13 33.3% 10.0 (4.9–15.1) *
Nodal 5 75.0% *
Both 4 0.0% *
Excision of recurrence
Complete 9 77.8% * <0.001
Not complete 13 0.0% 6.0 (4.6–7.4)
Interval to recurrence
>15 months 9 55.6% 17.0 (12.1–21.9) 0.013
615 months 13 10.9% 7.0 (5.1–8.9)
* No statistical analysis due to small number of cases in subgroups.
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